Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting133%
unknown267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

NCT06782451
unknown

The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

NCT02809898
unknown

Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

NCT02931981

Clinical Trials (3)

Showing 3 of 3 trials
NCT06782451Not Applicable

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Recruiting
NCT02809898

The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

Unknown
NCT02931981

Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Unknown

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3